In summary, the observations of this study showed that the combination of FZLZD and XELOX plus sintilimab in the treatment of advanced GC can significantly reduce TCM syndrome scores, reduce serum tumor marker levels and IL6 expression, and enhance the therapeutic effect of advanced GC. Here, IL6 is linked to neoplasm.